Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

GlycoVaxyn

Request full access

Company developing a broad portfolio of bioconjugate vaccines to prevent common bacterial infections using its proprietary glycoprotein technology

Zurich, SwitzerlandFounded 2004Biotech & Life Sciences

About GlycoVaxyn

GlycoVaxyn AG was a Swiss-based biotechnology company that operated in the vaccine development sector, specifically targeting the prevention and treatment of severe bacterial infections. The company was established in 2004 as a spin-off from the Swiss Federal Institute of Technology in Zurich (ETHZ). Its foundation was rooted in the doctoral research of co-founder Michael Wacker, who, alongside Urs Tuor and Michael Stucky, envisioned a new method for creating glyco-conjugate vaccines. Wacker, holding a Ph.D. in microbiology from ETHZ, served as the Chief Scientific Officer, translating his academic work into the company's core technology. In 2008, Philippe Dro, an experienced entrepreneur with a track record in life science transactions, was appointed CEO to steer the company's corporate development.

The company's business model centered on leveraging its proprietary in-vivo glycoengineering and bioconjugation platform. This technology enabled the production of complex conjugate vaccines within simple E. coli bacterial cells, a process designed to be faster, more reliable, and less expensive than traditional chemical conjugation methods. GlycoVaxyn's primary clients and partners were major pharmaceutical companies. The firm's revenue generation strategy involved upfront payments, equity investments, and potential milestone payments and royalties from licensing its vaccine candidates. This was exemplified by strategic collaborations with Janssen Pharmaceuticals and, most notably, GlaxoSmithKline (GSK).

The core of GlycoVaxyn's offering was its biological conjugation platform. This technology synthesizes protein-polysaccharide complexes using recombinant DNA technology inside E. coli, which simplifies the manufacturing process for conjugate vaccines. These vaccines are crucial for preventing bacterial infections like pneumonia and meningitis. The platform's main benefit was its potential to develop vaccines for bacterial pathogens that were previously difficult to target. The company's pipeline included vaccines in development for infections such as Shigellosis, pneumonia, Pseudomonas, and Staphylococcus aureus. The journey culminated in February 2015, when GSK, which had been a minority shareholder since 2012, acquired the remaining shares of GlycoVaxyn for $190 million, bringing the total valuation to $212 million.

Source: Dealroom company data

At a glance

Status
Acquired
Founded
2004
Headquarters
Zurich, Switzerland
Employees
2
Open positions
None listed
Dealroom signal
57.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Vaccines, Spinout, Biotech and Pharma, Hard Tech, Horizon Europe, DT and LS, science-based, Swiss DT Biotech
Business model
Manufacturing
Client focus
B2B

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Feb 2015 $190M $190M GSK —
SERIES B✓Equity / VC Mar 2009 $21M $85M Index Ventures · Sofinnova Partners · Andera Partners —
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowth
2026
2025
2024
2023
2022
2021
2020 —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

GlycoVaxyn website traffic

Latest recorded traffic for GlycoVaxyn is 310 monthly website visits, down 90.6% over the last three months. GlycoVaxyn's team grew 0% over the past year.

Latest monthly visits310 3-month web change-90.6% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

GlycoVaxyn in the Zurich ecosystem

Live from Dealroom

The GlycoVaxyn office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

Other known investors3 additional known investors

  • ETH Zurich
  • Grow Cluster Wädenswil
  • GSK
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇭 Switzerland · Zurich HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about GlycoVaxyn on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See GlycoVaxyn’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.